MedTrace Logo

Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies

NCT07732426 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-07-28

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate how semaglutide affects the way the brain responds to food in adults with obesity and food addiction tendencies.

The main goals of this study are:

* To see if semaglutide changes dopamine-related activity in the brain during the look, smell, and drink period.
* To see if semaglutide changes dopamine-related brain signals during the post-ingestive period.
* To see if semaglutide changes psychological survey results and cognitive task results.

Adults with obesity and food addiction tendencies will join this study. Each participant will receive semaglutide treatment for 8 weeks. Each participant will have two brain scans using \[11C\]raclopride PET.

During each PET scan, participants will:

* View food images.
* Receive chocolate milk through a tube while lying in the scanner.
* Use a tablet during the scan to rate their hunger, desire for the chocolate milk drink, and liking of the drink.

Conditions

Interventions

DRUG

Semaglutide

Participants receive an 8-week subcutaneous semaglutide dose-escalation treatment using Wegovy: 0.25 mg once weekly for the first 4 weeks, followed by 0.5 mg once weekly for the next 4 weeks.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Hyung Jin Choi, MD, PhD · Seoul National University College of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2028-02-29
Completion
2028-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07732426 on ClinicalTrials.gov